Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6months' first-line DMARD therapy - 06/03/07
, Michel de Bandt b, Jean-Marie Berthelot c, Alain Cantagrel d, Bernard Combe e, Bruno Fautrel f, René-Marc Flipo g, Frédéric Lioté h, Jean-Francis Maillefert i, Alain Saraux j, Daniel Wendling k, Francis Guillemin l, Xavier Le Loët m
Corresponding author. Tel.: +33 1 4025 7403; fax: +33 1 4229 0688.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Background |
The objective was to develop a clinical practice format for choosing a second-line disease-modifying anti-rheumatic drug (DMARD) after a 6-month course of a first-line DMARD in patients with early RA.
Methods |
A panel of 34 experts selected treatment option from various scenarios using the Thurstone pairwise method. The experts had to choose between two proposed DMARDs without proposing other options. The scenarios were obtained using the three items: DAS28, rheumatoid factor status and radiographic structural damage. A sample of 240 among 480 scenarios for each expert was taken at random. Responses given by at least 20% of the experts were considered pertinent.
Results |
Recommendations for choosing a second DMARD for early RA after failure of a 6-month course of a first-line DMARD were established according to 4 parameters: type of first-line DMARD, activity, RF status and radiographic joint damage. The results of this study suggest that in patients with early RA who fail a 6-month course of first-line DMARD therapy, the best options may be addition of corticosteroid when disease activity is moderate to high and switching to a biologic agent when further radiographic joint damage occurs, particularly in patients with positive tests for RF.
Conclusion |
Although our scenarios did not include step-up (add instead of substitute) strategies, except for corticosteroids, we feel that the format presented here can optimise the management of patients with early RA seen in clinical practice.
Le texte complet de cet article est disponible en PDF.Keywords : Rheumatoid arthritis, DMARDs, Therapeutic strategy
Plan
 | STPR group; Club Rhumatismes et Inflammation (CRI) of the French Society of Rheumatology. |
Vol 74 - N° 1
P. 73-78 - janvier 2007 Retour au numéro
Article précédent
- Cardiovascular disease in rheumatoid arthritis: Single-center hospital-based cohort study in France
- Noémie Assous, Emmanuel Touzé, Christophe Meune, André Kahan, Yannick Allanore
- Calcaneous quantitative ultrasound measurements predicts vertebral fractures in idiopathic male osteoporosis
- Szilvia Mészáros, Edit Tóth, Viktória Ferencz, Emõke Csupor, Éva Hosszú, Csaba Horváth
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?